TORONTO, ON / ACCESSWIRE / January 27, 2022 / AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company committed to acquiring and advancing Artificial Intelligence/Machine Learning technologies that address urgent societal needs, is pleased to announce that its minority-owned subsidiary, Tech2Heal SAS, has been selected to participate in the mental health innovation accelerator called IMPACT. Tech2Heal's "Qookka Mental Health Platform" was one of only five projects selected to participate in the program, from amongst a large number of applicants. The winning candidates benefit from a 9-month support program to accelerate their deployment, with significant involvement of IMPACT's founding partners.
IMPACT is an innovative public/private partnership formed to develop or accelerate novel solutions to remedy disruptions in the mental health care of adults. The 10 founding members of IMPACT comprise some of the finest health industry organizations, and include Janssen Pharmaceuticals (Johnson&Johnson), ARIIS (Health Industry Alliance for Research and Innovation), PSL University, Eisai (Japanese pharmaceutical), Otsuka Pharmaceutical, AXA (multinational insurance company), France Biotech (biotechnology trade association), PariSante Campus (e-health research park), Fédération Française de l'Assurance (French Insurance Federation), and Assistance Publique-Hôpitaux de Paris (university hospital).
The impetus for this initiative is the need to rapidly address the significantly deteriorating mental health of the French people. Today, 12 million people in France are afflicted with mental disorders. The projects chosen for IMPACT, such as Tech2Heal's Qookka, are tasked with creating solutions along the mental illnesses health pathway in one or more of the following sectors: access to care, care and follow-up, or out-of-hospital continuity.
Tech2Heal is a Paris, France based digital healthcare innovator with a portfolio of wellness and health-tech products and services designed to improve an individual's mental well-being by utilizing a unique blend of proprietary digital assets, remote live counselling, and a physical wellness center. Tech2Health has developed a clinically supported and evidence-based methodology consisting of psychotherapies and non-medicinal interventions that apply body and mind healing techniques, delivered via a secure digital platform.
Tech2Health's premier product, Qookka Live, provides mental and emotional health preventive and support services to corporations and health insurers from within one cohesive app. Qookka Live affords simple, intuitive access to licensed therapists and their patients, and supplements these consultations with both digital courses and live sessions of wellness coaching in six areas: meditation, mindfulness, yoga, art therapy, Tai chi and Qi Qong.
About AI/ML Innovations Inc.
AI/ML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through strategic partnerships with Health Gauge (70% owned by AIML), Tech2Heal (22% ownership commitment by AIML), AI Rx Inc. (70% owned by AIML) and other planned accretive investments, the Company continues to capitalize on expanding growth areas, to the benefit of all the Company's stakeholders. AI/ML's shares are traded on the Canadian Securities Exchange under the symbol "AIML", the OTCQB Venture Market under "AIMLF", and the Frankfurt Stock Exchange under "42FB".
On behalf of the Board of Directors Tim Daniels, Executive Chairman
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Cautionary and Forward-Looking Statements
Certain information in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including but not limited to, the uncertainty of competition by other industry players, the impact of general economic conditions, industry conditions, dependence upon regulatory approvals and the ability to raise additional capital as may be needed in the future. Readers are cautioned that the assumptions used in preparing such information, although considered reasonable at the time of preparation, may prove imprecise and undue reliance should not be placed on forward-looking statements. Forward-looking statements in this press release are expressly qualified by this cautionary statement.
The forward-looking statements in this press release are made as of the date of this press release, and the Company undertakes no obligations to update publicly or to revise any of the included forward-looking statements, whether because of new information, future events or otherwise, except as expressly required by applicable securities law.
